Whether the administration of FGF-21 analogs to achieve supraphysiological FGF-21 concentrations are definitely beneficial or not for NASH may hopefully be shown by the ongoing clinical trials. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.